JPH10510527A - 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用 - Google Patents
架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用Info
- Publication number
- JPH10510527A JPH10510527A JP8518473A JP51847396A JPH10510527A JP H10510527 A JPH10510527 A JP H10510527A JP 8518473 A JP8518473 A JP 8518473A JP 51847396 A JP51847396 A JP 51847396A JP H10510527 A JPH10510527 A JP H10510527A
- Authority
- JP
- Japan
- Prior art keywords
- powder
- microcapsules
- group
- particles
- fine particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 35
- 239000011859 microparticle Substances 0.000 title abstract description 11
- 229940126585 therapeutic drug Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 46
- 229940079593 drug Drugs 0.000 claims abstract description 43
- 239000000843 powder Substances 0.000 claims abstract description 25
- 239000000725 suspension Substances 0.000 claims abstract description 21
- 238000001694 spray drying Methods 0.000 claims abstract description 19
- 238000004132 cross linking Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000000524 functional group Chemical group 0.000 claims abstract description 8
- 239000010419 fine particle Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000006065 biodegradation reaction Methods 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000011243 crosslinked material Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 230000000717 retained effect Effects 0.000 abstract description 5
- 238000001212 derivatisation Methods 0.000 abstract description 3
- 239000002195 soluble material Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 description 110
- 102000009027 Albumins Human genes 0.000 description 14
- 108010088751 Albumins Proteins 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011257 shell material Substances 0.000 description 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001361 intraarterial administration Methods 0.000 description 5
- 229960002009 naproxen Drugs 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CXUAEBDTJFKMBV-UHFFFAOYSA-N 1-(chloromethyl)-2,3,4,5,6-pentamethylbenzene Chemical compound CC1=C(C)C(C)=C(CCl)C(C)=C1C CXUAEBDTJFKMBV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000239290 Araneae Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010064129 Thrombogen Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000005440 nitrobenzoic acid derivatives Chemical class 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 架橋した物質の、直径が0.1〜50μmの滑らかな球形の微細粒子か らなる無菌の粉末。ただし、この微細粒子は親水性であり、且つ水で再形成させ ると単分散懸濁液をもたらすことができるものであり、またこの粉末は、微細粒 子上の遊離官能基を介して直接的、もしくは間接的に微細粒子と結合している生 理学的に有効な、もしくは診断上有効な成分を付加的に含んでなるものである。 2. 該物質が、アミノ酸、ポリアミノ酸、もしくはその他のポリペプチドで ある、請求項1に記載の粉末。 3. 酵素による生分解を促進する水溶性の物質を更に含んでいる、請求項1 もしくは2に記載の粉末。 4. 該有効成分が薬剤、化学スペーサー、酵素もしくは受容体に対するリガ ンド、又は抗体である、先行する請求項のいずれか一項に記載の粉末。 5. 水溶性であって、且つ該基をもつ該物質から、下記(i)及び(ii) により得られる、先行する請求項のいずれか一項に記載の粉末。 (i)該基が遊離した状態に保たれるように噴霧乾燥、及び架橋を行う工程。 (ii)該基を介して架橋した物質に有効成分を結合させる工程。 6. 工程(i)が、該水溶性物質の溶液を噴霧乾燥させ、乾燥させた物質を 4%未満の水分の存在下で加熱して架橋させることからなる、請求項5に記載の 粉末。 7. 該官能基がアミン基、ヒドロキシル基、カルボキシル基、もしくはスル フヒドリル基である、先行する請求項のいずれか一項に記載の粉末。 8. 該官能基がアミン基、ヒドロキシル基、もしくはカルボキシル基である 、請求項7に記載の粉末。 9. 該粒子の四分位範囲と平均直径との比が0.2〜0.5である、先行す る請求項のいずれか一項に記載の粉末。 10. 該粒子の95%が6μm未満であり、且つ該粒子の80%が1〜6μ mの範囲にある、請求項9に記載の粉末。 11. 該粒子の90%が20μm未満であり、且つ5体積%未満が6μm未 満である、請求項9に記載の粉末。 12. 非経口投与に適した、先行する請求項のいずれか一項に記載の微細粉 末の懸濁液。 13. 該微細粒子が請求項10に記載されているものであって、静脈内投与 用のものである、請求項12に記載の懸濁液。 14. 該微細粒子が請求項11に記載されているものであって、動脈内投与 用のものである、請求項12に記載の懸濁液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94309417 | 1994-12-16 | ||
GB94309417.7 | 1994-12-16 | ||
PCT/GB1995/002925 WO1996018388A2 (en) | 1994-12-16 | 1995-12-14 | Cross-linked microparticles and their use as therapeutic vehicles |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10510527A true JPH10510527A (ja) | 1998-10-13 |
JP4350165B2 JP4350165B2 (ja) | 2009-10-21 |
Family
ID=8217949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51847396A Expired - Fee Related JP4350165B2 (ja) | 1994-12-16 | 1995-12-14 | 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0796090B1 (ja) |
JP (1) | JP4350165B2 (ja) |
CN (1) | CN1175208A (ja) |
AT (1) | ATE234080T1 (ja) |
AU (1) | AU692019B2 (ja) |
BR (1) | BR9510462A (ja) |
CA (1) | CA2207077C (ja) |
CZ (1) | CZ183797A3 (ja) |
DE (1) | DE69529917T2 (ja) |
DK (1) | DK0796090T3 (ja) |
ES (1) | ES2191721T3 (ja) |
FI (1) | FI972546A (ja) |
HU (1) | HUT77369A (ja) |
NO (1) | NO972554D0 (ja) |
NZ (1) | NZ297072A (ja) |
PL (1) | PL321018A1 (ja) |
PT (1) | PT796090E (ja) |
WO (1) | WO1996018388A2 (ja) |
ZA (1) | ZA9510702B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010515062A (ja) * | 2006-12-29 | 2010-05-06 | アボット・ラボラトリーズ | 非変性細胞溶解試薬 |
JP2011529946A (ja) * | 2008-08-05 | 2011-12-15 | コアセラピクス エスエルユー | 直径10〜20μmのマイクロスフェアを含む非経口組成物 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US5955108A (en) * | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
EP0914096B1 (en) * | 1996-05-17 | 2003-08-13 | Elan Drug Delivery Limited | Microparticles and their use in wound therapy |
GB9610830D0 (en) | 1996-05-23 | 1996-07-31 | Andaris Ltd | Use of hollow microcapsules |
GB9615435D0 (en) * | 1996-07-23 | 1996-09-04 | Andaris Ltd | Spray-dried product and its therapeutic use |
GB9621825D0 (en) * | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
WO1998017318A1 (en) * | 1996-10-19 | 1998-04-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules in diagnosis and therapy |
EP1028752B1 (en) * | 1996-10-21 | 2004-12-15 | Quadrant Drug Delivery Limited | Platelet substitutes and conjugation methods suitable for their preparation |
US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
EP0964676A1 (en) * | 1997-01-30 | 1999-12-22 | Quadrant Healthcare (UK) Limited | Microparticles and their use in cancer treatment |
AU741528B2 (en) | 1997-06-05 | 2001-12-06 | Hemosphere, Inc. | Fibrinogen-coated microspheres |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
GB9724143D0 (en) * | 1997-11-14 | 1998-01-14 | Andaris Ltd | Pharmaceutical conjugate |
GB9825105D0 (en) * | 1998-11-16 | 1999-01-13 | Andaris Ltd | Pharamaceutical conjugates |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
CA2468958C (en) | 2001-12-19 | 2012-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
CA2750725C (en) * | 2004-01-07 | 2014-10-21 | Seikagaku Corporation | Spacer derivative for hyaluronic acid and non-steroidal anti-inflammatory drug residues |
GB0623607D0 (en) | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
EP2216054A1 (en) | 2009-02-06 | 2010-08-11 | ProFibrix BV | Biodegradable extravascular support |
GB0909136D0 (en) | 2009-05-28 | 2009-07-01 | Profibrix Bv | Dry powder composition |
GB0909131D0 (en) | 2009-05-28 | 2009-07-01 | Quadrant Drug Delivery Ltd | Dry powder fibrin sealant |
KR20120125465A (ko) | 2010-01-08 | 2012-11-15 | 프로피브릭스 비.브이. | 건조 분말 피브린 실란트 |
NO20110653A1 (no) | 2011-05-02 | 2012-11-05 | Spiro Medical As | Respirasjonsovervakning |
RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0494417B1 (en) * | 1991-01-10 | 1996-04-17 | Basf Corporation | Process for crosslinking gelatin and for incorporation a material therein |
GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
-
1995
- 1995-12-14 PT PT95940381T patent/PT796090E/pt unknown
- 1995-12-14 BR BR9510462A patent/BR9510462A/pt not_active Application Discontinuation
- 1995-12-14 CZ CZ971837A patent/CZ183797A3/cs unknown
- 1995-12-14 JP JP51847396A patent/JP4350165B2/ja not_active Expired - Fee Related
- 1995-12-14 WO PCT/GB1995/002925 patent/WO1996018388A2/en active IP Right Grant
- 1995-12-14 CN CN95197597A patent/CN1175208A/zh active Pending
- 1995-12-14 AU AU41849/96A patent/AU692019B2/en not_active Ceased
- 1995-12-14 NZ NZ297072A patent/NZ297072A/xx unknown
- 1995-12-14 PL PL95321018A patent/PL321018A1/xx unknown
- 1995-12-14 ES ES95940381T patent/ES2191721T3/es not_active Expired - Lifetime
- 1995-12-14 HU HU9701980A patent/HUT77369A/hu unknown
- 1995-12-14 DK DK95940381T patent/DK0796090T3/da active
- 1995-12-14 CA CA002207077A patent/CA2207077C/en not_active Expired - Fee Related
- 1995-12-14 AT AT95940381T patent/ATE234080T1/de not_active IP Right Cessation
- 1995-12-14 DE DE69529917T patent/DE69529917T2/de not_active Expired - Fee Related
- 1995-12-14 EP EP95940381A patent/EP0796090B1/en not_active Expired - Lifetime
- 1995-12-15 ZA ZA9510702A patent/ZA9510702B/xx unknown
-
1997
- 1997-06-05 NO NO972554A patent/NO972554D0/no not_active Application Discontinuation
- 1997-06-16 FI FI972546A patent/FI972546A/fi unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010515062A (ja) * | 2006-12-29 | 2010-05-06 | アボット・ラボラトリーズ | 非変性細胞溶解試薬 |
JP2011529946A (ja) * | 2008-08-05 | 2011-12-15 | コアセラピクス エスエルユー | 直径10〜20μmのマイクロスフェアを含む非経口組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0796090A2 (en) | 1997-09-24 |
CA2207077C (en) | 2007-02-06 |
PL321018A1 (en) | 1997-11-24 |
WO1996018388A3 (en) | 1996-08-29 |
CN1175208A (zh) | 1998-03-04 |
AU692019B2 (en) | 1998-05-28 |
MX9704503A (es) | 1997-10-31 |
DK0796090T3 (da) | 2003-06-23 |
ATE234080T1 (de) | 2003-03-15 |
ZA9510702B (en) | 1996-12-17 |
HUT77369A (hu) | 1998-03-30 |
FI972546A0 (fi) | 1997-06-16 |
FI972546A (fi) | 1997-07-04 |
NO972554L (no) | 1997-06-05 |
ES2191721T3 (es) | 2003-09-16 |
EP0796090B1 (en) | 2003-03-12 |
WO1996018388A2 (en) | 1996-06-20 |
NO972554D0 (no) | 1997-06-05 |
DE69529917D1 (de) | 2003-04-17 |
DE69529917T2 (de) | 2003-12-11 |
NZ297072A (en) | 1999-03-29 |
AU4184996A (en) | 1996-07-03 |
PT796090E (pt) | 2003-07-31 |
JP4350165B2 (ja) | 2009-10-21 |
BR9510462A (pt) | 1998-12-15 |
CZ183797A3 (en) | 1997-11-12 |
CA2207077A1 (en) | 1996-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4350165B2 (ja) | 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用 | |
US5955108A (en) | Cross-linked microparticles and their use as therapeutic vehicles | |
US5972707A (en) | Gene delivery system | |
CA2145505C (en) | Microparticle preparations made from biodegradable copolymers | |
EP0553299B1 (en) | Efficient microcapsule preparation and method of use | |
JP5147699B2 (ja) | タンパク質ナノ粒子およびその使用 | |
US7855180B2 (en) | Structure and method for releasing substance therefrom | |
JP2001504813A (ja) | 代用血小板、及びそれらの製造に適した抱合法 | |
JP2001503407A (ja) | 改良された診断/治療用薬剤 | |
JP2001511765A (ja) | 改良された診断/治療用薬剤 | |
JPH09507680A (ja) | 赤血球代用剤 | |
US6383470B1 (en) | Microparticle preparations made of biodegradable copolymers | |
US20040258761A1 (en) | Polymer-based microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production | |
JP2001523648A (ja) | 2種の活性剤を含むコンジュゲート | |
Hata et al. | Preparation of CM-chitin microspheres by complexation with iron (III) in w/o emulsion and their biodisposition characteristics in mice | |
Magee et al. | Effect of process variables on the in vitro degradation of protein microspheres | |
MXPA97004503A (en) | Steril powder of interlocked materials and its | |
Namazi | A Modified Polymeric Nano-formulation to Control Binding and Release of Insulin | |
KR920003166B1 (ko) | 약물-고분자 공유결합체를 사용한 미립구의 제조방법 | |
Tomlinson et al. | Albumin microspheres for intraarterial drug targeting | |
JP2001502719A (ja) | 改良された診断/治療用薬剤 | |
MXPA99003677A (en) | Platelet substitutes and conjugation methods suitable for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060926 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20061129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080418 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081028 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090302 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090317 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090623 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090722 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120731 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |